BTIG Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $87
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Jeet Mukherjee initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $87.
BTIG analyst Jeet Mukherjee initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $87.